H.B. Fuller (FUL) Q4 2025 earnings review
Margins Surge, But Volumes Vanish
H.B. Fuller delivered a textbook case of 'shrinking to greatness' in Q4. While net revenue declined 3.1% YoY (missing expectations) and volumes contracted 2.5%, the company engineered a massive profitability beat. Adjusted EBITDA margins expanded 290 basis points to 19.0%, and Adjusted EPS surged 39% to $1.28. The disconnect between falling sales and rising profits highlights strong pricing power and cost actions, but the FY26 guidance (Revenue Flat to +2%) suggests the volume headwinds are far from over.
🐂 Bull Case
Management delivered on the 'price vs. raw material' spread. Adjusted Gross Margin hit 32.5% (+290bps YoY), and EBITDA margins reached 19.0%. HHC margins specifically recovered from 13.9% a year ago to 17.5%, proving the pricing actions worked.
Despite a tough industrial backdrop, Engineering Adhesives (the highest margin segment) grew volumes and expanded margins to a stellar 23.5%. This mix shift is structurally improving the company's profitability profile.
🐻 Bear Case
Organic revenue decline accelerated to -1.3% in Q4, driven by a -2.5% volume drop. This is worse than Q3 (-1.9% volume). The 'unpredictable economic backdrop' cited by management is actively hurting top-line demand.
Despite higher profits, Net Working Capital rose to 15.8% of sales (up 130bps YoY), and Operating Cash Flow fell to $263M (vs $302M in FY24). Management blames 'footprint optimization' inventory builds, but it's a drag on returns.
⚖️ Verdict: ⚪
Neutral. The EPS growth (+39%) is impressive, but the quality of growth is low. You cannot cut costs and raise prices forever while volumes shrink (-2.5%). Until organic volume turns positive, the upside is capped.
Key Themes
Building Adhesive Solutions (BAS) Reverses Course
Reversing. A year ago (24Q4), Construction Adhesives was the star, growing organic sales 10.5%. In 25Q4, the realigned BAS segment revenue fell 3.3%, with margins compressing to 15.2%. The tailwind from roofing and infrastructure has dissipated, turning a former growth driver into a drag.
Hygiene, Health & Consumables (HHC) Margin Recovery
Accelerating. HHC was the disaster story of late 2024 (13.9% margin). It has staged a massive recovery to 17.5% margin in 25Q4, driven by pricing actions and lower raw material costs. While revenue growth is tepid (+1.2%), the profitability restoration in this segment is the primary driver of the corporate earnings beat.
Inventory Build / Cash Flow Drag
Operating Cash Flow for FY25 dropped to $263M from $302M in FY24, despite significantly higher Net Income. Management cites 'higher inventory days on hand' to support manufacturing footprint optimization. Net working capital expanded to 15.8% of sales. This inefficiency contradicts the 'lean' narrative.
Engineering Adhesives (EA) Profitability
Stable/Positive. EA remains the crown jewel. Revenue grew 4.1% (outperforming the corporate average), and margins expanded 260bps YoY to 23.5%. The mix shift toward high-spec applications (electronics, automotive) continues to support the valuation multiple.
Macro Uncertainty
Management cited an 'unpredictable economic backdrop' and a 'challenging demand landscape.' This vagueness, combined with the volume declines (-2.5%), suggests they have limited visibility into a true demand recovery for 2026.
Other KPIs
Accelerating. Up 290 basis points YoY. This is the highest level in recent quarters, driven by pricing sticking while raw material costs eased. This is the engine of the EPS beat.
Decelerating. Deteriorated from -1.9% in Q3 and +1.3% in 24Q4. The pricing power is real, but it is costing volume.
Stable. Down from 3.3x in Q3 and 3.5x in Q1. Deleveraging is progressing slowly due to the weaker cash flow generation.
Guidance
Stable/Low Growth. Organic revenue expected to be flat. This implies no real volume recovery in 2026, just stabilization. This is a sobering outlook compared to the 'growth' narrative.
Decelerating. The midpoint ($645M) implies ~4% growth over FY25 ($621M). This is a slowdown compared to the 14.6% growth seen in 25Q4. The margin expansion lever has likely been pulled as far as it can go without volume support.
Stable Growth. Midpoint implies ~6% growth vs FY25 ($4.24). A solid number, but far from the 39% growth explosion seen in Q4.
Accelerating slightly. Midpoint ($287.5M) is up ~9% from FY25's depressed $263M, but still below FY23 and FY24 levels. The 'footprint optimization' continues to consume cash.
Key Questions
Volume vs. Price Trade-off
Volumes deteriorated to -2.5% in Q4. At what point does the strategy shift from margin protection (pricing) to volume defense, especially given the flat organic guide for FY26?
BAS Segment Reversal
Building Adhesive Solutions swung from +10% growth a year ago to -3% decline. Is this purely a macro construction slowdown, or have we lost share in the roofing/infrastructure verticals?
Inventory & Cash Flow
Inventory days are elevated due to 'footprint optimization.' When specifically does this unwind and convert to cash? Why is FY26 OCF guidance still below FY24 levels despite higher projected EBITDA?
Q1 2026 Outlook
You guided Q1 26 revenue 'down low single digits.' Given the easy comp from 25Q1 (-2.7% decline), why is the start of the year still negative?